SEC Filing Summary: Amedica Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amedica Corporation on April 5, 2016, covering events that occurred on April 4, 2016. The filing details a material definitive agreement involving the restructuring of existing debt and the issuance of new convertible securities and warrants to Riverside Merchant Partners, LLC ("Riverside").
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data relates to the debt restructuring transaction:
- Debt Assignment: Hercules Capital sold $1,000,000 of the principal amount of Amedica's Term Loan to Riverside. An option exists for Riverside to purchase an additional $2,000,000.
- Debt Exchange: Amedica exchanged $1,000,000 of the Term Loan held by Riverside for a new Subordinated Convertible Promissory Note ("First Exchange Note") of $1,000,000.
- Warrant Issuance: A warrant was issued to purchase 100,000 shares of common stock at an exercise price of $1.62 per share.
- Note Terms: The First Exchange Note bears 6% annual interest. The principal is convertible at $1.43 per share. Maturity is March 3, 2018, or 91 days after the Term Loan is paid in full.
- Additional Exchange Option: Parties may exchange an additional $2,000,000 of the Term Loan for a similar note and a warrant for 100,000 shares by May 3, 2016.
Material Changes and Unusual Items
The filing reports a significant change in the company's capital structure through the conversion of senior term loan debt into subordinated convertible debt and equity-linked instruments. Key unusual items and conditions include:
- Price Protection: If the volume-weighted average price of the common stock is below the conversion price ($1.43) for 20 trading days following issuance, the company must issue an additional 150,000 shares to the holder.
- Prepayment Penalty: Prepayment of the note after the Term Loan is satisfied requires a premium of 115% of the prepaid amount.
- Interest Payment Flexibility: Interest may be paid in cash or shares (at $1.34 per share) at the company's option prior to maturity, subject to conditions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future business performance. Risks are inherent in the new debt structure, including:
- Dilution Risk: Conversion of the note and exercise of warrants could result in the issuance of approximately 699,300 shares (from the note) plus 100,000 shares (from the warrant), with potential for additional shares if price protection triggers.
- Liquidity Constraints: The company faces potential cash outflows for interest payments or prepayment premiums if conditions are not met to pay in stock.
- Default Penalties: The note contains default events that could trigger additional interest and penalties.
Investor Verification Checklist
- Verify the current outstanding balance of the Term Loan to assess the potential impact of the optional $2,000,000 additional exchange.
- Confirm the current trading price of Amedica's common stock relative to the $1.43 conversion price and $1.62 warrant exercise price to evaluate immediate dilution risk.
- Review the full text of the Assignment Agreement (Exhibit 10.1) and Exchange Agreement (Exhibit 10.2) for specific conditions regarding interest payment in stock and default triggers.
- Assess the company's cash position to determine its ability to service the 6% interest or meet the 115% prepayment premium if required.